** Traws Pharma's TRAW.O shares soar 129% to $11.30 premarket

** TRAW says its experimental bird flu drug, tivoxavir marboxil, was safe and well-tolerated in early-stage trial

** A single dose maintained levels of the drug in the blood for over 23 days in the trial, co says

** Mid-stage trial is expected to begin in H1 2025, co says

** Bird flu has infected more than 860 dairy herds in 16 U.S. states since March and killed 123 million poultry since the outbreak began in 2022

** As of last close, stock has fallen 73.2% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))